Get the Stockscreener App
1.40
0.72%
0.01
Pre-market:
1.41
0.01
+0.71%
Opko Health Inc stock is traded at $1.40, with a volume of 1.62M.
It is up +0.72% in the last 24 hours and up +13.82% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.39
Open:
$1.41
24h Volume:
1.62M
Relative Volume:
0.47
Market Cap:
$1.04B
Revenue:
$581.12M
Net Income/Loss:
$-212.92M
P/E Ratio:
-5.1132
EPS:
-0.2738
Net Cash Flow:
$-174.22M
1W Performance:
+6.06%
1M Performance:
+13.82%
6M Performance:
+13.82%
1Y Performance:
+3.70%
1-Day Range:
$1.39
$1.425
1-Week Range:
$1.32
$1.425
52-Week Range:
$0.9769
$1.73
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.40 | 1.04B | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
595.89 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.89 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
310.78 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
566.93 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
149.29 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | JP Morgan | Neutral |
| Oct-31-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Analysts - MarketBeat
OPKO Health, Inc. Expands Strategic Relationship with Healthcare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests - marketscreener.com
OPKO Health secures $125m financing backed by mazdutide royalties - Investing.com
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests - OPKO Health, Inc.
OPKO Health Issues Additional $125 Million in Senior Notes Secured by Mazdutide Royalties - marketscreener.com
OPKO Health raises $125M in notes backed by mazdutide royalties - StreetInsider
OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties - Stock Titan
Opko Health, Inc. (OPK) Stock Analysis: Exploring A 214.75% Potential Upside - DirectorsTalk Interviews
Does OPKO Health’s Sharply Narrowed Q2 Loss Reset the Bull Case for OPKO Health (OPK)? - Sahm
OPKO Health Inc (OPK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opko Health | SCHEDULE 13D: Others - Moomoo
OPKO Health: Mazdutide And MDX-2201 Could Change Everything (NASDAQ:OPK) - Seeking Alpha
OPKO Health invests $5 million in Cocrystal Pharma By Investing.com - Investing.com South Africa
Weekly Recap: Q2 2026 financial results and MDX trial timelines - TradingView
Cocrystal Pharma Raises $5 Million in Private Placement With OPKO Health at $0.9134/Share - TradingView
Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health - Stock Titan
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewswire
OPKO Buys 5.47M Cocrystal Shares Ahead of Late-2026 Norovirus Data - Stock Titan
Opko Health Earnings Call Highlights Pipeline, Profit Pivot - The Globe and Mail
Opko Health Launches Early MASH Trial That Could Shape Its Next Growth Chapter - The Globe and Mail
OPKO Health: A Hold As Progress Continues (NASDAQ:OPK) - Seeking Alpha
Opko Health, Inc. Revenue Breakdown – NASDAQ:OPK - TradingView
OPKO Health (OPK) Is Up 14.1% After Narrower Q2 Loss and New 2026 Revenue Guidance – Has The Bull Case Changed? - simplywall.st
Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - 富途牛牛
Cocrystal Pharma, Inc. announced that it has received $5 million in funding from OPKO Health, Inc. - marketscreener.com
OPKO Health Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), AbbVie (ABBV) - The Globe and Mail
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results - Benzinga
OPKO Health (NASDAQ:OPK) Shares Gap Up Following Strong Earnings - MarketBeat
Why Is OPKO Health (NASDAQ:OPK) Stock Drawing Fresh Market Interest Today? - Kalkine Media
Piper Sandler Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3 - Moomoo
OPK Looks 19.0% Overvalued on GF Value™ - GuruFocus
Opko Health, Inc. (OPK) Stock Analysis: Exploring a 252.82% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Opko Health | 4: Statement of changes in beneficial ownership of securities-Officer Rubin Steven D - Moomoo
OPKO Health, Inc. 2026 Q2 10-Q Report: Financial Statements, Risk Factors, and Management Discussion - Minichart
OPK Looks 17.9% Overvalued on GF Value™ - GuruFocus
OPKO Health Q2 2026 Results: Key Pipeline Advances, Rayaldee China Expansion, and Improved Financial Performance – Minichart - Minichart
OPKO Health (NASDAQ:OPK) Shares Rise After Q2 Earnings Exceed Forecasts; Nicoya Agreement Lifts After-Hours Gains - TechStock²
Earnings call transcript: OPKO Health posts smaller Q2 loss, shares rise in 2026 - Investing.com Canada
OPK: Q2 2026 delivered higher revenue, improved margins, and raised full-year guidance amid pipeline advances - TradingView
OPKO Health Q2 Earnings Call Highlights - MarketBeat
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
OPK: Profitability improved and revenue grew in Q2 2026, with guidance raised for the full year - TradingView
OPK Looks 17.0% Overvalued on GF Value™ - GuruFocus
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
OPKO Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OPKO Health Q2 EPS beats estimates as sales rise 4.3% to $163.5 million - scanx.trade
OPKO Health (NASDAQ:OPK) Issues Earnings Results - MarketBeat
OPKO HEALTH ($OPK) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
0.28%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):